Cystic Changes in Intraabdominal Extrahepatic Metastases from Gastrointestinal Stromal Tumors Treated with Imatinib

Objective

This study was undertaken for the purpose of describing the CT features of intra-abdominal extra-hepatic metastases from gastrointestinal stromal tumors in patients who were treated with imatinib.

Materials and Methods

Eleven patients with intra-abdominal extra-hepatic metastases from gastrointestinal stromal tumors, who were treated with imatinib between May 2001 and December 2003, were included in this study. The clinical findings and CT scans were retrospectively reviewed. The metastatic lesions were assessed according to the location, size (greatest diameter), attenuation, and the enhancing pattern before and after imatinib treatment.

Results

Prior to the treatment, the sizes and attenuation values of the metastatic lesions ranged from 5 to 20 cm and from 63 to 131 H, respectively. The metastatic lesions showed a heterogeneous enhancement pattern on the contrast-enhanced CT scans. After the treatment, the metastatic lesions became smaller in all 11 patients, and the corresponding attenuation value ranged from 15 to 51 H. The metastatic lesions became homogeneous and cystic in appearance on the follow-up CT scans, mimicking ascites.

Conclusion

Intra-abdominal extra-hepatic metastases of patients with gastrointestinal stromal tumors treated with imatinib may appear as well-circumscribed cystic lesions on contrast-enhanced CT. These metastases are likely to become smaller and resemble ascites, but may persist indefinitely on the follow-up CT.     

Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases

Purpose  

To prospectively evaluate the predictive value of various bone formation and resorption markers in patients with bone metastases from prostate cancer after palliative treatment with ¹⁸⁶Re-1,1-hydroxyethylidene diphosphonate (¹⁸⁶Re-HEDP).     

Micronucleus evaluation for determining the chromosomal breakages after radionuclide synovectomy in patients with hemophilia

Objective  

To investigate the genotoxic effects of ⁹⁰Y and ¹⁸⁶Re in patients with hemophilia who were undergoing radionuclide synovectomy (RS) procedure in the last 3 years.     

Radiation dosimetry and biodistribution of <Superscript>99m</Superscript>Tc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer

Purpose  

To assess the radiation dosimetry and biodistribution of ^99mTc-labeled ethylene dicysteine deoxyglucose (^99mTc-EC-DG) in patients with non-small-cell lung cancer (NSCLC).     

Treatment of metastatic,imatinib refractory,gastrointestinal stroma tumor with image-guided high-dose-rate interstitial brachytherapy

Purpose

Evaluation of efficacy and safety of CT- or MRI-guided high-dose-rate interstitial brachytherapy (iBT) in the treatment of advanced, imatinib refractory, metastatic gastrointestinal stroma tumors (GISTs) was the objective of this retrospective study.

Relation of <Superscript>99m</Superscript>Tc-sestamibi washout with myocardial properties in patients with hypertrophic cardiomyopathy

Background  

We sought to determine the relationship between ^99mTc-sestamibi washout and myocardial properties in hypertrophic cardiomyopathy (HCM) patients.     

Technetium 94m-labeled methoxyisobutyl isonitrile: Dosimetry and resting cardiac imaging with positron emission tomography

Background  

Development of a positronemitting form of technetium has allowed the imaging of technetium radiopharmaceuticals with positron emission tomography (PET). We used^94mTc to compare the distribution of the myocardial perfusion agent sestamibi at rest with the conventional PET perfusion tracer¹³N-labeled ammonia (¹³N-ammonia).     

<Superscript>18</Superscript>F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with <Superscript>90</Superscript>Y microspheres

Purpose  

⁹⁰Y radioembolization has emerged as a valuable therapy for intrahepatic cholangiocellular carcinomas (ICC). We aimed to evaluate the prognostic power of FDG PET/CT and that of pretherapeutic scintigraphy with ^99mTc-labelled macroagglutinated albumin (MAA), an index of tumour vascularization.     

PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG

Purpose  

The aim of this study was to evaluate inflammation and tumour imaging with a vascular adhesion protein 1 (VAP-1) targeting peptide ⁶⁸Ga-DOTAVAP-P1 in comparison with ¹⁸F-FDG.     

<Superscript>18</Superscript>F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging

Purpose  

The aim of the study was to assess the utility of ¹⁸F-fluorocholine (FCH), compared to standard imaging of bone scan (BS) and contrast-enhanced abdominopelvic computed tomography (CT), in patients with castration-resistant prostate carcinoma.     

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

Purpose  

The aim of this retrospective study was to determine whether patients with previous peptide receptor radionuclide therapy using high-activity ¹¹¹In-pentetreotide can be safely treated with ¹⁷⁷Lu-octreotate and whether addition of radiosensitising chemotherapy increases the toxicity of this agent.     

Effects of therapy with [<Superscript>177</Superscript>Lu-DOTA<Superscript>0</Superscript>,Tyr<Superscript>3</Superscript>]octreotate on endocrine function

Purpose  

Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues is a novel therapy for patients with somatostatin receptor-positive tumours. We determined the effects of PRRT with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate (¹⁷⁷Lu-octreotate) on glucose homeostasis and the pituitary-gonadal, pituitary-thyroid and pituitary-adrenal axes.     

Synchronous malignancies in patients with squamous cell carcinomas of the oral cavity

Purpose  

Synchronous malignancies in patients with squamous cell carcinomas of the oral cavity (OCSCC) are occasionally encountered. In the current study we tried to evaluate their frequency, detectability by ¹⁸F-fluorodeoxyglucose (FDG) studies, and prognostic factors.     

Combined therapy with <Superscript>131</Superscript>I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer

Purpose  

The aim of this study was to assess the clinical outcome of redifferentiation therapy using retinoic acid (RA) in combination with ¹³¹I therapy, and to identify biological parameters that predict therapeutic response in Korean patients with radioiodine-refractory papillary thyroid carcinoma (PTC).     

Feasibility of <Superscript>62</Superscript>Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease

Purpose  

[⁶²Cu]Diacetyl-bis(N ⁴-methylthiosemicarbazone) (⁶²Cu-ATSM) was used to evaluate brain haemodynamic impairment in patients with cerebrovascular disease (CVD) as a simplified evaluation method. The tracer distribution was compared with haemodynamic parameters obtained by ¹⁵O positron emission tomography (PET).     

The relationship between reverse redistribution of 99mTc-tetrofosmin in sub-acute phase and left ventricular functional recovery in chronic phase in patients with acute myocardial infarction

Objective  

The purpose of this study was to clarify the relationship between reverse redistribution (RRD) of ^99mTc-tetrofosmin (^99mTc-TF) and left ventricular functional recovery in patients with acute myocardial infarction (AMI).     

Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl

Purpose  

The objective of this project was to systematically determine the prevalence and consequences of pulmonary fibrosis in youth with thyroid carcinoma and lung metastases from Belarus who were treated with radioiodine (¹³¹I).     

A meta-analysis of <Superscript>18</Superscript>FDG-PET,MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer

Objective  

To perform a meta-analysis comparing the diagnostic value of ¹⁸FDG-PET, MRI, and bone scintigraphy (BS) in detecting bone metastases in patients with breast cancer.     

Effects of food intake and anesthetic on cardiac imaging and uptake of BMS747158-02 in comparison with FDG

Background  

BMS747158-02 is an ¹⁸F-labeled agent being developed for PET myocardial perfusion imaging. This study examined impacts of feeding state and anesthetic on cardiac imaging and uptake of this agent in rats in comparison with ¹⁸F-fluorodeoxyglucose (FDG).     

PET with 18F-labelled choline-based tracers for tumour imaging: a review of the literature

Purpose  

To give an up-to-date overview of the potential clinical utility of ¹⁸F-labelled choline derivatives for tumour imaging with positron emission tomography.